cb

CB1 antagonist 2 (AM4113) is caimabinoid 1 (CB1) antagonist which inhibits CB1 in vivo with an IC50 of 25.5 nM.

CB1-IN-1 (DBPR211) is a peripherally restricted CB1R antagonist, for CB1R and CB2R with Ki of 0.3 nM and 21 nM,respectively.

CB1 antagonist 4 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes.

CB-6644 is a small molecule inhibitor of the ATPase activity of the RUVBL1/2 complex. It specifically interacts with RUVBL1/2 in cancer cells and blocks the ATPase activity of RUVBL1/2 with a half-maximal inhibitory concentration (IC50) of 15 nM[1].

CB2 modulator 1 is a potent CB2 modulator. It can be used for the research for immune disorders, osteoporosis, inflammation, renal ischemia.

CB29 is a specific inhibitor of aldehyde dehydrogenase 3A1 (ALDH3A1).

CB1 antagonist 1 is a CB1 receptor antagonist, used in the research of obesity and metabolic syndrome, neuroinflammatory disorders, cognitive disorders, and gastrointestinal disorders, psychosis, and cardiovascular.

CB1151, a 20-epi analogue of 1,25-dihydroxyvitamin D3, exhibits anti-tumor effects by inhibiting MCF-7 cell growth (IC50: 0.82 nM).

CB2R-IN-1 is a potent inverse agonist of the cannabinoid CB2 receptor (Ki: 0.9 nM).

CB 300919 is a quinazoline-based antitumor agent exhibiting high activity against CH1 human ovarian tumor xenografts, with continuous exposure (96 h) resulting in a growth inhibition (IC50: 2 nM).

CB-7921220 (6-[2-(4-Aminophenyl)vinyl]-2-pyridinecarboxylic acid) is an inhibitor of adenylate cyclase.

CB30865 (ZM 242421) is a selective and highly effective nicotinamide phosphoribosyltransferase (Nampt) inhibitor with potential antitumor activity.

KH-CB19 is an effective and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4).

GP 2A is a selective agonist of CB2 receptor.

KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and CLK4, with an IC50 of 16.5 nM for CLK1. KH-CB20 also inhibits DYRK1A (IC50 = 57.8 nM) and CLK3 (IC50 = 488 nM).

CB-5083 is a potent, selective, and orally bioavailable p97 AAA ATPase inhibitor ( IC50=11 nM).

CB-83 is a novel G6PD inhibitor.

CB5255829 is a novel inhibitor of Mycobacterium marinum MelF (Rv1936), exhibiting bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro.

CB-64D is a sigma2R selective agonist which releases calcium in human neuroblastoma cells and produces cell death in tumor cell lines.

CB5660386 inhibitor of HIV-1 entry.

CB-1158-analog, also known as Numidargistat-analog and INCB01158-analog, is a potent and orally active arginase inhibitor with IC50=89 nM) . CB-1158 blocked myeloid cell-mediated suppression of T cell proliferation in vitro and reduced tumor growth in multiple mouse models of cancer, as a single agent and in combination with checkpoint blockade, adoptive T cell therapy, adoptive NK cell therapy, and the chemotherapy agent gemcitabine. CB-1158 increased tumor-infiltrating CD8+ T cells and NK cells, inflammatory cytokines, and expression of interferon-inducible genes. CB-1158 may be potentially useful in renal cell cancer, breast cancer, non-small cell lung cancer, acute myeloid leukemia, and other tumor types where arginase-secreting MDSCs are known to play an immunosuppressive role. (see ADDITIONAL INFORMATION in this web page for CB-1158 structure confusion).

CB6513745 is a novel inhibitor of Mycobacterium marinum MelF (Rv1936), exhibiting bacteriostatic/bactericidal activity against M. marinum and M. tuberculosis in vitro.

CB-892 is a novel inhibitor of hiv-1 gene expression

Telaglenastat (CB 839) (IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC.